Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
about
Nitrofurantoin is active against vancomycin-resistant enterococciIn vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.Clinical features and prognosis of spontaneous bacterial peritonitis in korean patients with liver cirrhosis: a multicenter retrospective study.Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristinIn vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.Importance of atypical pathogens of community-acquired pneumonia.Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients.In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents.Linezolid for the treatment of resistant gram-positive cocci.Novel targets for the future development of antibacterial agents.The role of genomics in the discovery of novel targets for antibiotic therapy.Resistance to linezolid. Are we surprised? How hard should we look?Fungal infection but not type of bacterial infection is associated with a high mortality in primary and secondary infected pancreatic necrosis.Oxidative cyclizations in orthosomycin biosynthesis expand the known chemistry of an oxygenase superfamilyAnti-MRSA agents: under investigation, in the exploratory phase and clinically available.Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates.Single cell analysis of gene expression patterns of competence development and initiation of sporulation in Bacillus subtilis grown on chemically defined media.Linezolid: effectiveness and safety for approved and off-label indications.Presence of variations in ribosomal protein L16 corresponding to susceptibility of enterococci to oligosaccharides (Avilamycin and evernimicin).Pharmacokinetics of a new parenteral oligosaccharide antibiotic, SCH27899 (Ziracin), in healthy subjects.Incidence of high-level evernimicin resistance in Enterococcus faecium among food animals and humans.Evaluation of a fully automated system (RAISUS) for rapid identification and antimicrobial susceptibility testing of Staphylococci.Quinupristin/dalfopristin: the first available macrolide-lincosamide-streptogramin antibiotic.Unnoticed spread of class 1 integrons in gram-positive clinical strains isolated in Guangzhou, China.Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.Bactericidal effect of gentamicin-induced membrane vesicles derived from Pseudomonas aeruginosa PAO1 on gram-positive bacteria.The influence of antibiotic use on the occurrence of vancomycin-resistant enterococci.Antimicrobial resistance in Staphylococcus aureus, Streptococcus uberis and Streptococcus dysgalactiae from dairy cows with mastitis.Microwave-Facilitated SPOT-Synthesis of Antibacterial Dipeptoids.Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program.Linezolid for the treatment of skin and soft-tissue infections
P2860
Q24550619-B9A83E4A-B6A3-4E45-85D4-601E6CF89476Q30612482-A5518FEE-CE2B-4B7A-86A1-6866A8CFA3CAQ33781627-FD15BF92-BE23-4C2C-BCE9-B71A4D86E4CDQ33968684-C5C95692-51FC-480C-84A2-0EDFF9379EAEQ33979559-BEEED8C0-625E-4CE9-B640-22663595E675Q33981431-4CAB7065-9420-4D6B-B5C6-EE85A4943ED4Q34030766-5E90D2D9-2ABE-457B-9B16-85BA9F16E254Q34052619-CBE37152-70AA-484B-A5E3-437C948C386AQ34110412-977D070F-3A82-4543-8922-413C855CC0F3Q34193591-87C6186F-4FC8-4F0E-934F-974090341FA5Q34247278-2ECF6FE8-0398-442C-9B71-B10ED266B6D2Q34631428-9A092EF2-9B2C-46A2-8607-541F73B6734CQ34673339-C1B1D9FD-7C6E-46D7-842F-602CB266BE33Q35139266-0E42F9E1-FEC8-462F-BA65-F97916245018Q35886354-889A6FE6-5E56-4C1C-9BCB-8075981F2A14Q36079165-7593DF55-B746-4059-861A-EA14B021D92DQ36233502-DC9F5ADD-C2FA-4F9C-A49E-06A7C67F8565Q36492132-D9B16B39-2842-423F-A915-E5657E87DD6DQ36565136-F5CFB8A8-03BB-4B10-BFFA-34445236FE3DQ36967288-BFBD5545-342E-4D65-931B-035BAE722C2EQ39475744-EECD7C62-BDA5-444F-B742-27BAECD637E7Q39476658-74D7F583-F229-40ED-BCA8-A42A336ADBB2Q39652720-4E329721-AE97-4ACF-A6FA-35973D77CF25Q39804876-0AD78EEC-4636-4580-9201-F1332AD0F9D5Q40561137-5346301B-C85F-40C7-B404-D8D4DA5E93B4Q43169004-E4348C9F-CEC3-46C5-B56F-AF02CB605A51Q43587155-742BFC30-9FAC-4BB0-8802-6576F7D27F17Q44232054-6B495BC1-20DC-4075-AC8B-3115A85EC0F4Q46942527-F79E0D07-C92C-4AE4-BF99-6D76689DA5C9Q46973130-D8182091-527F-4E01-AF0F-AECF36E44F63Q48181421-C9BD3F1D-351A-4308-AF9F-4F5A7550AA98Q54011822-627815EC-5EE4-4BF8-95EC-BE73D5C19216Q56268956-B4322222-9DB6-4E92-9082-922EF661CA57
P2860
Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Epidemiologic trends in nosoco ...... ins and other newer compounds.
@ast
Epidemiologic trends in nosoco ...... ins and other newer compounds.
@en
Epidemiologic trends in nosoco ...... ins and other newer compounds.
@nl
type
label
Epidemiologic trends in nosoco ...... ins and other newer compounds.
@ast
Epidemiologic trends in nosoco ...... ins and other newer compounds.
@en
Epidemiologic trends in nosoco ...... ins and other newer compounds.
@nl
prefLabel
Epidemiologic trends in nosoco ...... ins and other newer compounds.
@ast
Epidemiologic trends in nosoco ...... ins and other newer compounds.
@en
Epidemiologic trends in nosoco ...... ins and other newer compounds.
@nl
P2093
P1476
Epidemiologic trends in nosoco ...... ins and other newer compounds.
@en
P2093
P304
P356
10.1016/S0732-8893(98)00108-4
P577
1999-02-01T00:00:00Z